UGCG inhibitors were shown to reduce tumor volume and tumor size in vivo models of renal cancer and melanoma [24, 25], respectively, and decreased proliferation of leukemic [5], prostate [26], breast [27], and glioma cancer cells [28]. Here, UGCG is linked to renal carcinoma.